Arthritis News and Research RSS Feed - Arthritis News and Research Twitter

Many people start to feel pain and stiffness in their bodies over time. Sometimes their hands or knees or shoulders get sore and are hard to move and may become swollen. These people may have arthritis. Arthritis may be caused by inflammation of the tissue lining the joints. Some signs of inflammation include redness, heat, pain, and swelling. These problems are telling you that something is wrong. Joints are places where two bones meet, such as your elbow or knee. Over time, in some types of arthritis but not in all, the joints involved can become severely damaged. There are different types of arthritis. In some diseases in which arthritis occurs, other organs, such as your eyes, your chest, or your skin, can also be affected. Some people may worry that arthritis means they won’t be able to work or take care of their children and their family. Others think that you just have to accept things like arthritis.
Researchers identify enzyme that controls spread of breast cancer

Researchers identify enzyme that controls spread of breast cancer

Researchers at the University of California, San Diego School of Medicine have identified an enzyme that controls the spread of breast cancer. The findings, reported in the current issue of PNAS, offer hope for the leading cause of breast cancer mortality worldwide. [More]
Study to measure and estimate global ablation market

Study to measure and estimate global ablation market

Reportbuyer.com has added a new market research report: Ablation Devices: Technologies and Global Markets. [More]
Fitness expert urges trainers to be cautious and not over train young athletes

Fitness expert urges trainers to be cautious and not over train young athletes

Texas fitness expert Bobby Whisnand urges coaches, trainers and parents to be cautious and not over train young athletes preparing for the upcoming football season. [More]
Research roundup: Benefits of hip surgery; preventing surgical infections; assessing ACOs' predecessors

Research roundup: Benefits of hip surgery; preventing surgical infections; assessing ACOs' predecessors

Surgical treatment of hip fractures can achieve better survival and functional outcomes than nonoperative treatment, but less is known about its economic benefits. ... We estimated the effects of surgical treatment for displaced hip fractures through a Markov cohort analysis of patients 65 years and older. ... Estimated average lifetime societal benefits per patient exceeded the direct medical costs of hip fracture surgery by $65,000 to $68,000 for displaced hip fractures. With the exception of the assumption of nursing home use, the sensitivity analyses show that surgery produces positive net societal savings (Gu, Koenig, Mather and Tongue, 8/5). [More]
Obama's plans for vets include development of computer chips to stop pain

Obama's plans for vets include development of computer chips to stop pain

The novel effort will be spearheaded by the Defense Advanced Research Projects Agency. Also, Sen. Bernie Sanders, I-Vt., tells an American Legion convention that Congress will continue to revamp the VA. [More]
Knee pain when using stairs early clue to OA

Knee pain when using stairs early clue to OA

Feeling knee pain during weight-bearing activities involving knee bending, such as using stairs, could be an early sign of osteoarthritis and the need for intervention, research indicates. [More]
Many people with severe rheumatoid arthritis failing to take expensive medication

Many people with severe rheumatoid arthritis failing to take expensive medication

Large numbers of people with severe rheumatoid arthritis are failing to take expensive medication as prescribed, according to a new multi-centre study led by researchers in Manchester. [More]
Microtechnologies to tackle problems of mobility industry and life sciences

Microtechnologies to tackle problems of mobility industry and life sciences

CIC microGUNE, the Co-operative Research Centre into Microtechnologies, is coordinating the microSCALE project which seeks to generate innovative solutions based on microtechnologies to tackle the problems of the mobility industry and life sciences, among others. [More]
First Edition: August 28, 2014

First Edition: August 28, 2014

Today's headlines include reports about the Congressional Budget Office's latest projections regarding Medicare and Medicaid spending. [More]
New technology may pinpoint minor strains in body's tissues long before injuries occur

New technology may pinpoint minor strains in body's tissues long before injuries occur

Researchers at Washington University in St. Louis have developed algorithms to identify weak spots in tendons, muscles and bones prone to tearing or breaking. [More]
Patients with mild osteoarthritis may not benefit from knee surgery

Patients with mild osteoarthritis may not benefit from knee surgery

A new study indicates that there is no apparent benefit to arthroscopic knee surgery for age-related tears of the meniscus in comparison with nonsurgical or sham treatments. [More]
Cilag GmbH International acquires biopharmaceutical company, Covagen AG

Cilag GmbH International acquires biopharmaceutical company, Covagen AG

Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired Covagen AG, a privately-held, biopharmaceutical company specializing in the development of multispecific protein therapeutics through the FynomAb® technology platform. [More]
Reduce inflammatory reaction by losing weight, says researcher

Reduce inflammatory reaction by losing weight, says researcher

Researchers have found a possible molecular explanation for why overweight is harmful. This new knowledge may provide new drugs for heart attack, stroke, cancer and chronic intestinal inflammation. [More]
Sanofi, Regeneron present alirocumab Phase 3 trial results at ESC Congress 2014

Sanofi, Regeneron present alirocumab Phase 3 trial results at ESC Congress 2014

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that details from four pivotal trials in the alirocumab ODYSSEY clinical program will be presented on Sunday, August 31, during a Hot Line session at ESC Congress 2014 in Barcelona, Spain, the world's largest cardiology meeting. [More]
Study finds a host of new clues on gene-environment interactions in Crohn's disease

Study finds a host of new clues on gene-environment interactions in Crohn's disease

A new study finds a wide range of epigenetic changes-alterations in DNA across the genome that may be related to key environmental exposures-in children with Crohn's disease (CD), reports Inflammatory Bowel Diseases, official journal of the Crohn's & Colitis Foundation of America. [More]
Race and ethnicity influence outcomes of patients with motor complete SCI

Race and ethnicity influence outcomes of patients with motor complete SCI

Researchers have published a study examining racial and ethnic influences in the outcomes of patients with motor complete spinal cord injury (SCI). The article, "Racial and ethnic disparities in functioning at discharge and follow-up among patients with motor complete SCI," was published online ahead of print on August 2 by the Archives of Physical Medicine & Rehabilitation. [More]
Three commonly used NSAIDs affect cell membranes, produce unwanted side effects

Three commonly used NSAIDs affect cell membranes, produce unwanted side effects

Researchers have discovered that three commonly used nonsteroidal anti-inflammatory drugs, or NSAIDs, alter the activity of enzymes within cell membranes. Their finding suggests that, if taken at higher-than-approved doses and/or for long periods of time, these prescription-level NSAIDs and other drugs that affect the membrane may produce wide-ranging and unwanted side effects. [More]
Highlights from the August issue of Mayo Clinic Health Letter

Highlights from the August issue of Mayo Clinic Health Letter

Here are highlights from the August issue of Mayo Clinic Health Letter. You may cite this publication as often as you wish. Reprinting is allowed for a fee. Mayo Clinic Health Letter attribution is required. [More]
Lilly’s ixekizumab superior to placebo, etanercept on all skin clearance measures in Phase 3 studies

Lilly’s ixekizumab superior to placebo, etanercept on all skin clearance measures in Phase 3 studies

Eli Lilly and Company's investigational medicine ixekizumab was statistically superior to etanercept and placebo on all skin clearance measures in Phase 3 studies, the company said today in disclosing top-line results from its pivotal UNCOVER studies in moderate-to-severe plaque psoriasis. [More]
Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announces the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody. [More]